ADAMTS1

Across TCGA pan-cancer cohorts, ADAMTS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAMTS1 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ADAMTS1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADAMTS1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where ADAMTS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.628	0.913	.008	17	view →
LSCC	OS	Median	II,III,IV	0.900	1.000	.015	8	view →
LUAD	OS	Median	II,III,IV	1.000	0.501	.022	5	view →
PDAC	OS	Median	II,III,IV	0.666	0.391	.045	2	view →
GBM	OS	Median	All	0.603	0.411	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAMTS1–CCRCC (OS)

Open the CCRCC breakdown →